We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Specific Cytokines Are Significant Biomarkers for AML

By LabMedica International staff writers
Posted on 16 Oct 2019
Print article
Image: Myeloperoxidase positive staining from a patient with acute myeloid leukemia (Photo courtesy of Monika Nema, MD).
Image: Myeloperoxidase positive staining from a patient with acute myeloid leukemia (Photo courtesy of Monika Nema, MD).
Acute myeloid leukemia is a hematopoietic neoplasm derived from early progenitor myeloid cells; it is characterized by clonal expansion of myeloblasts, which are immature myeloid progenitors that accumulate in the bone marrow (BM).

Immune system impairment and immunetolerance were reported in patients with acute myeloid leukemia. T cells are the most active part of the immune system, nevertheless they were found to be functionally and numerically defective in acute myeloid leukemia. Interleukin-27 (IL27) and IL35 are regulatory T cells (T-regs) related cytokines; they may be involved in eukemogenesis of acute myeloid leukemia (AML).

Scientists at Sohag University (Sohag, Egypt) recruited 70 newly diagnosed patients with primary AML and 30 matched healthy volunteers. The diagnosis of AML in the patients was made using Leishman-stained peripheral blood smears; Bone marrow (BM) aspirates or occasionally trephine biopsy; Cytochemical staining of BM specimens using myeloperoxidase (MPO), esterase and periodic acid Schiff; and immunophenotyping (IPT): monoclonal antibodies (MoAb) used for staining of blast cells were labeled with fluorescein isothiocyanate, phycoerythrin.

Serum was obtained from plain blood sample tubes that were kept at −80 °C by centrifugation. Serum levels of IL-27 and IL-35 were measured by enzyme-linked immunosorbent assay (ELISA), for both patients and controls, using the commercially available kits. Absorbance was recorded at 495 nm, IL-27 assay range was 31.25–2,000 pg/mL, and IL-35 assay range was 15.63–1,000 pg/mL. The median age of the study patients was 36 years and the range was 18–80 years. Females comprised 52.9% of the patient group.

The scientists reported that significantly higher levels of IL27 and IL35 in AML patients compared with the control subjects, with median values of 77 and 51 pg/mL compared to 37 and 22.2 pg/mL, respectively. The correlations between serum levels of IL27 and IL3 in AML patients, revealed a significant positive correlation between IL27 with, white blood cell (WBCs) count, peripheral blasts percent and myeloperoxidase (MPO) positivity. However, IL35 levels showed a significant negative correlation with platelets count and significant positive correlations with age, CD45, HLA-DR and CD34.

The authors concluded that their study demonstrated that IL27 and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique they recommended the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML. The study was published on October 1, 2019, in the Journal of Blood Medicine.

Related Links:
Sohag University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more